A longtime research leader at Penn Wynne’s Lankenau Medical Center is being recognized nationally for his impact on medical innovation, according to Main Line Health.
George Prendergast, PhD, president and CEO of the Lankenau Institute for Medical Research, has been elected a Fellow of the National Academy of Inventors. The acknowledgment is the highest professional distinction awarded exclusively to inventors. He is among 185 U.S. and international innovators named to the Academy’s 2025 class.
Over his 21-year tenure, Dr. Prendergast has helped cultivate a culture that connects academic research with real-world invention. He coined the term “ACAPRENEURIAL” to describe this hybrid approach. This resulted in a growing number of patented devices, diagnostic tests, and treatments addressing cancer, cardiovascular disease, and other complex conditions.
LIMR scientists have also increased their academic research output to record levels during this period.
Dr. Prendergast is an accomplished cancer researcher with more than 180 published papers and is listed as an inventor or co-inventor on 50 published or pending patents. His recent work includes advancing IDO inhibitors, a promising class of drugs aimed at improving immune response and treatment outcomes in cancer therapy.
To learn more about Dr. Prendergast’s achievements, visit PR Newswire.
